Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016853 | 0.83 | EPHX1 (0.37) | EPHX1NR1H2PREPCHRM2CHRM1 | |
| SCHEMBL6016852 | 0.83 | EPHX1 (0.37) | EPHX1NR1H2PREPCHRM2CHRM1 | |
| SCHEMBL6016798 | 0.80 | MEN1 (0.39) | EPHX1NR1H2PREPCHRM2CHRM1 | |
| SCHEMBL6016799 | 0.80 | MEN1 (0.39) | EPHX1NR1H2PREPCHRM2CHRM1 | |
| SCHEMBL7564909 | 0.79 | EPHX1 (0.36) | EPHX1NR1H2PREPCHRM2CHRM1 | |
| SCHEMBL501214 | 0.77 | NR1H2 (0.35) | EPHX1NR1H2PREPCHRM2CHRM1 | |
| SCHEMBL2493223 | 0.74 | CHRM2 (0.37) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL2498342 | 0.74 | CHRM2 (0.37) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL875047 | 0.72 | CHRM2 (0.36) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL2119472 | 0.72 | CHRM2 (0.36) | NR1H2CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855708-B2 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030008861-A1 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008861-A1 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ITGA4 | EPHX1 2999/4885NR1H2 1059/4885PREP 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.